Cyclo TherapeuticsCYTH
13F holders, Q3 2024 (September 30)19holders −3
0new positions
3sold out
$0.79avg. 13F price*
At the end of Q3 2024, 19 institutions reported holding Cyclo Therapeutics Inc. (CYTH) in their 13F filings, down 3 from Q2 2024. 0 opened new positions and 3 sold out. The largest holders were EPIQ Capital Group, LLC ($583K), Vanguard Group Inc. ($472K) and Founders Fund V Management, LLC ($379K).
- Company
- Cyclo Therapeutics Inc.
- CUSIP
- 23254X201
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $48K |
All 13F filers, Q2 2024 → Q3 2024: 156,822 shares bought and 139,277 shares sold, net +17,545 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| EPIQ Capital Group, LLC | 0.17% | Reduce -9.5% | 739,426 | $583K |
| Vanguard Group Inc. | 0.00% | Add +34.1% | 598,694 | $472K |
| Founders Fund V Management, LLC | 66.35% | No change | 480,708 | $379K |
| Geode Capital Management, LLC | 0.00% | Reduce -13.2% | 152,332 | $120K |
| Founders Fund VI Management, LLC | 100.00% | No change | 110,023 | $87K |
| BlackRock, Inc. | 0.00% | — | 83,521 | $66K |
| State Street Corp. | 0.00% | No change | 39,530 | $31K |
| Wealth Enhancement Advisory Services, LLC | 0.00% | Add +14.7% | 23,400 | $18K |
| Northern Trust Corp. | 0.00% | No change | 21,722 | $17K |
| UBS Group AG | 0.00% | Add +3.4% | 12,458 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +7.9% | 5,395 | $4K |
| Wells Fargo & Company | 0.00% | No change | 4,391 | $3K |
| Princeton Global Asset Management LLC | 0.00% | Reduce -8.0% | 3,466 | $3K |
| Royal Bank of Canada | 0.00% | Add +10.1% | 821 | $1K |
| Morgan Stanley | 0.00% | No change | 1,031 | $813 |
| Bank of America Corp. | 0.00% | Add +373.3% | 994 | $784 |
| JPMorgan Chase & Co. | 0.00% | Add +26.8% | 194 | $153 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 90 | $71 |
| Osaic Holdings, Inc. | 0.00% | No change | 67 | $52 |
"% of holder's portfolio" is CYTH's weight in each manager's 13F, not the share of Cyclo Therapeutics Inc. the manager owns.